ArticleAlzheimer's & dementia (New York, N. Y.)
Estimating preclinical amyloid positivity: A case study transporting ADNI to ARIC.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estimating preclinical amyloid positivity: A case study transporting ADNI to ARIC.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionAlzheimer's disease and related dementias researchers have benefited from deeply phenotyped clinical samples; however, there is a critical need for estimates that generalize to diverse, representative populations. Use of a statistical approach from causal inference, "transport," may allow generalization of findings from clinical samples to other target populations. Here we explore the feasibility and validity of extending results from a clinical sample, the Alzheimer's Disease Neuroimaging Initiative (ADNI), to a community-based target sample, the Atherosclerosis Risk in Communities Study Positron Emission Tomography Amyloid Imaging Study (ARIC-PET) using transport estimation and a standard approach, direct standardization, which itself can be considered a simple transport.
methodsEligible ARIC-PET (
resultsApproximately half of transported prevalences were closer to observed ARIC-PET prevalences than the crude ADNI prevalences, including in all five subgroups in which crude prevalences differed substantially across cohorts. However, for many subgroups, transported prevalences were substantially further from observed ARIC-PET prevalences than crude ADNI prevalences. Standardization produced more variable estimates, which were not systematically closer to observed ARIC-PET prevalence than the crude ADNI prevalence estimates. Restriction to more homogenous samples did not improve performance of either method. DISCUSSION: Although transport performed better than direct standardization in this example, available data appear insufficient to generalize findings from convenience samples to less selected samples with high confidence using either method. Recruitment of diverse, representative samples will likely be needed to derive population-level statistics given limitations of legacy samples. Highlights: Prior prevalence estimates of amyloid positivity are variable.Transport may improve generalization from samples to target populations.We standardized and transported estimates to a target with known prevalence.Neither worked reliably; transport performed better than standardization.Clinical convenience samples are inadequate to derive population-level statistics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.